Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?

Eur J Cancer. 2020 Aug:135:75-77. doi: 10.1016/j.ejca.2020.04.046. Epub 2020 Jun 15.

Authors

L Mans¹, M Pezzullo², N D'Haene³, J Van de Stadt⁴, J-L Van Laethem⁴

Affiliations

¹ Gastroenterology, Hepato-pancreatology, Digestive Oncology and Surgery Department, Erasme Hospital, Brussels, Université Libre de Brussels, Belgium. Electronic address: [email protected].
² Department of Radiology, Erasme Hospital, Brussels, Université Libre de Brussels, Belgium.
³ Department of Pathology, Erasme Hospital, Brussels, Université Libre de Brussels, Belgium.
⁴ Gastroenterology, Hepato-pancreatology, Digestive Oncology and Surgery Department, Erasme Hospital, Brussels, Université Libre de Brussels, Belgium.

PMID: 32554216
DOI: 10.1016/j.ejca.2020.04.046

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / genetics
Adenocarcinoma / immunology
Adenocarcinoma / pathology
Adenocarcinoma / therapy*
Adult
Antineoplastic Agents, Immunological / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Chemotherapy, Adjuvant
Digestive System Surgical Procedures
Female
Humans
Immune Checkpoint Inhibitors / administration & dosage*
Ipilimumab / administration & dosage*
Microsatellite Instability*
Neoadjuvant Therapy*
Neoplasm Staging
Nivolumab / administration & dosage*
Rectal Neoplasms / genetics
Rectal Neoplasms / immunology
Rectal Neoplasms / pathology
Rectal Neoplasms / therapy*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Ipilimumab
Nivolumab